Question explored with the scientific record
Are snake eggs used in vaccines?
The short version: no, snake eggs are not used in vaccines. The idea appears to come from a mix-up with chicken eggs and snake venom research.
None of the 21 evidence records retrieved mention snake eggs as a vaccine ingredient. What the records do show is that chicken eggs are used in two completely separate ways: to grow influenza virus for flu vaccines [17], and to produce antivenom antibodies (IgY) from egg yolks of immunized hens [4]. That second use is for snakebite treatment, not for vaccines. The confusion likely comes from the word "snake" appearing in studies about snake venom antivenom [2, 3, 4] and snake phylogenetics [1], none of which involve vaccine production.
The evidence that does exist about egg use in vaccines is about chicken eggs, specifically for influenza vaccine manufacturing in MDCK cells grown in serum-free medium [17] and for potency testing of other vaccines [16]. No record describes snake eggs as a raw material, growth medium, or ingredient in any human vaccine.
My call: snake eggs are not used in vaccines. Confidence: high, based on the complete absence of any such use in the retrieved literature and the clear documentation of chicken eggs as the relevant egg-based system.
Sources used 6
-
Molecular systematics of New World lampropeltinine snakes (Colubridae): implications for biogeography and evolution of food habits
This study utilizes mitochondrial gene sequences to elucidate the phylogenetic relationships among North American lampropeltinine snakes, revealing significant insights into their biogeography and dietary evolution.
DOI: 10.1006/bijl.1999.0320 -
Inhibitory effects of Piper umbellatum and Piper peltatum extracts towards myotoxic phospholipases A2 from Bothrops snake venoms: Isolation of 4-nerolidylcatechol as active principle
Plant-derived Piper extracts inhibit venom phospholipase A2 enzymes from Bothrops snakes, with 4-nerolidylcatechol identified as the active inhibitor that reduces myotoxicity and edema in mice, though in vivo efficacy is limited by rapid toxin action.
DOI: 10.1016/j.phytochem.2005.03.026 -
Erythrocyte haemotoxicity profiling of snake venom toxins after nanofractionation
The study develops a high-throughput erythrocyte lysis assay integrated with nanofractionation to profile venom-induced haemolysis and identify specific haemolytic toxins across five medically important snakes, revealing elapid venoms contain both direct and indirect lytic toxin…
DOI: 10.1016/j.jchromb.2021.122586 -
CORAL SNAKE ANTIVENOM PRODUCED IN CHICKENS (Gallus domesticus)
The study demonstrates production of coral snake antivenom IgY in laying hens, purified from egg yolk, that neutralizes Micrurus venoms in mice with an ED50 of 477 mg/kg and shows cross-reactivity to multiple venoms, offering a noninvasive, scalable alternative to traditional ma…
DOI: 10.1590/s0036-46652014000100009 -
Replacement of in vivo human rabies vaccine potency testing by in vitro glycoprotein quantification using ELISA – Results of an international collaborative study
This study evaluates three different ELISA methods as in vitro alternatives to the NIH in vivo potency test for human rabies vaccines, demonstrating their ability to discriminate between potent and sub-potent vaccine batches.
DOI: 10.1016/j.vaccine.2016.12.039 -
Production of Inactivated Influenza H5N1 Vaccines from MDCK Cells in Serum-Free Medium
This study develops a high-yield, serum-free MDCK-cell–based manufacturing process for influenza A(H5N1) vaccines, demonstrating scalable production in microcarrier bioreactors with comparable antigenicity and mouse-immunogenicity to serum-containing methods and lower-cost opera…
DOI: 10.1371/journal.pone.0014578